Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

In This Article:

The Canadian market is experiencing strong momentum as it heads into 2025, supported by a resilient consumer base, rising corporate profits, and the beginning of a rate-cutting cycle. Amidst this positive backdrop, investors may find opportunities in areas that have traditionally been overlooked, such as penny stocks. While the term "penny stock" might seem outdated, these smaller or newer companies can still offer significant growth potential when backed by solid financials and fundamentals.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Alvopetro Energy (TSXV:ALV)

CA$4.33

CA$154.9M

★★★★★★

Amerigo Resources (TSX:ARG)

CA$1.71

CA$283.52M

★★★★★☆

Pulse Seismic (TSX:PSD)

CA$2.39

CA$120.08M

★★★★★★

PetroTal (TSX:TAL)

CA$0.63

CA$574.88M

★★★★★★

Mandalay Resources (TSX:MND)

CA$3.45

CA$324.12M

★★★★★★

Vox Royalty (TSX:VOXR)

CA$3.73

CA$187.19M

★★★★★★

Findev (TSXV:FDI)

CA$0.465

CA$13.03M

★★★★★☆

Foraco International (TSX:FAR)

CA$2.11

CA$212.76M

★★★★★☆

NamSys (TSXV:CTZ)

CA$1.14

CA$30.89M

★★★★★★

East West Petroleum (TSXV:EW)

CA$0.04

CA$3.62M

★★★★★★

Click here to see the full list of 959 stocks from our TSX Penny Stocks screener.

We'll examine a selection from our screener results.

InnoCan Pharma

Simply Wall St Financial Health Rating: ★★★★★★

Overview: InnoCan Pharma Corporation is a pharmaceutical technology company that develops drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients across the United States, Canada, Europe, and internationally, with a market cap of CA$65.99 million.

Operations: The company's revenue is primarily generated from online sales, amounting to $28.86 million.

Market Cap: CA$66M

InnoCan Pharma has demonstrated significant revenue growth, with third-quarter sales reaching US$8.62 million, doubling from the previous year. Despite being unprofitable, the company has reduced its net loss over recent periods and maintains a robust cash position with short-term assets of US$9.5 million covering both short- and long-term liabilities comfortably. The management team is experienced, aiding in strategic decisions like the FDA's positive response to their LPT-CBD product pathway, potentially expediting market entry. However, shareholder dilution occurred last year with a 7.1% increase in shares outstanding, which investors should consider when evaluating potential risks and rewards.

CNSX:INNO Debt to Equity History and Analysis as at Nov 2024
CNSX:INNO Debt to Equity History and Analysis as at Nov 2024

Taranis Resources

Simply Wall St Financial Health Rating: ★★★★★☆